

# Treating patients with medically resistant epilepsy

Gregory L. Krauss, MD  
Michael R. Sperling, MD

## Summary

Recent evidence suggests that medically resistant epilepsy can be identified if seizures persist despite adequate doses of 2 appropriate first-line antiepileptic drugs (AEDs). Patients with medically resistant epilepsy should have their seizures carefully characterized in order to confirm their diagnosis, select treatment, and assist in determining prognosis. Patients should be counseled about factors that aggravate epilepsy and the importance of adhering to treatments. Physicians should carefully inquire about side effects and alter therapy to eliminate or minimize these symptoms. Uncontrolled seizures cause injuries, disability, and increased mortality, so surgery should be considered as soon as seizures are proven to be medically resistant. Patients with incomplete response to AEDs and who are not surgical candidates may benefit from additional medication trials or from palliative nonmedical therapies, such as vagal nerve stimulation.

**W**hat is medically resistant epilepsy? Medically resistant epilepsy would seem to be a self-evident term, referring to patients whose seizures persist despite using antiepileptic drugs (AEDs). The definition, however, relies as much upon pharmacologic efficacy and physician treatment skills as the underlying biology and natural history of epilepsy. One might have hoped that the development of nearly a dozen new drugs for epilepsy in the 1990s and 2000s would have simplified this definition. Unfortunately, while many newer drugs have superior pharmacokinetic and side-effect profiles than older AEDs, they possess the same degree of effectiveness. These AEDs rarely stop seizures once older agents have failed. Hence, until innovative pharmaceutical approaches yield better response rates, we must conclude that medical resistance is biologically determined and innate in some forms of epilepsy.



Johns Hopkins University (GLK), Baltimore; and Thomas Jefferson University (MRS), Philadelphia.

**Correspondence to:** [gkrauss@jhmi.edu](mailto:gkrauss@jhmi.edu)

Drug-resistant epilepsy has been defined as the “failure of adequate trials of 2 tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapy or in combination) to achieve sustained seizure freedom.” This operational definition, established by an International League Against Epilepsy commission,<sup>1</sup> relies upon the observation that adults and children rarely achieve sustained seizure freedom once 2 agents have failed to control seizures.<sup>2–4</sup> The definition includes the important requirement that the drugs must be both appropriate for the patient’s seizure type and tolerated at therapeutic doses. For example, failure of ethosuximide to control complex partial seizures is not a valid drug failure since ethosuximide is ineffective for focal seizures. Similarly, a suitable dose must be used, so the patient who only tolerates a subtherapeutic dose of a particular AED cannot be considered to have failed to respond to that drug. Finally, the drug must be given a reasonable chance to work, and an excessively brief course of treatment is not adequate. Careful attention to these requirements should prevent inappropriate diagnosis of drug resistance.

### Why is it important to recognize medically resistant epilepsy?

Patients with frequent, severe seizures experience high rates of psychosocial disabilities, including undereducation, underemployment and unemployment, impaired socialization, and psychiatric disturbances.<sup>5,6</sup> They also have increased medical morbidity, with higher than expected injury rates and high mortality rates.<sup>6</sup> Attaining seizure control by nonmedical means can reverse some of the disability, morbidity, and mortality of refractory epilepsy.<sup>7,8</sup> Failure to acknowledge drug resistance may prevent patients from receiving alternative treatments that might be effective, such as epilepsy surgery.

One must consider seizure type, seizure effects, and epilepsy syndrome when thinking about drug-resistant epilepsy as they influence whether new medications or alternative therapies are needed. What kinds of seizures merit more aggressive therapy? The most common types are seizures producing loss of awareness, which can be disabling and pose medical and psychosocial risk. Uncontrolled complex partial seizures, and, especially, tonic-clonic seizures are associated with increased mortality, from sudden unexpected death in epilepsy (SUDEP) and other causes; this risk exceeds the risk of more aggressive interventions. Some seizures without loss of consciousness might be sufficiently disturbing to warrant pursuing new treatments as well (e.g., seizures producing vomiting or intense fear).

Seizures that cause injury (e.g., falling) also must be taken more seriously. Seizures with stigmatizing behavior (e.g., incontinence or disrobing) pose more difficulty than inconspicuous attacks. Similarly, seizures followed by profound postictal effects (e.g., extreme fatigue or sleepiness, cognitive impairment, or psychiatric disturbances) merit more aggressive therapy. By contrast, minor nondisabling seizures without these features might be deemed medically resistant, but are insufficiently problematic to warrant pursuing further diagnostic evaluation or therapy. The epilepsy syndrome matters, as well. One must establish whether the syndrome is static or progressive (e.g., progressive myoclonus epilepsy or Rasmussen syndrome) and whether it is potentially surgically remediable (e.g., mesial temporal sclerosis). Response to medication must always be put in context, considering what kind of seizures and epilepsy are present prior to making a decision about the next steps.<sup>9</sup>

### Steps to accurately diagnose and treat medically resistant epilepsy

**Confirm the patient has epilepsy (tables 1 and 2)** Seizures may not respond to AEDs if the patient does not have epilepsy. Common imitators of seizures include convulsive syncope (severe syncope causing jerking or shaking), psychogenic nonepileptic seizures (seizure-like behaviors), pain or panic reactions, and dissociative states.<sup>10</sup> Most seizure types and epilepsy can be accurately diagnosed by the presence of their typical clinical features. The EEG can often help confirm the seizure type and MRI is important to identify underlying causes for seizures. It is important to collect a careful history of key clinical features of seizures

**Table 1** Evaluating and treating medically resistant epilepsy**Identifying epilepsy and seizure types vs alternative disorders****Epilepsy**

- Partial-onset seizures: simple partial, complex partial, secondary generalized tonic clonic
- Primary generalized epilepsy: childhood and juvenile absence, myoclonic, tonic clonic
- Severe symptomatic (multifocal epilepsy, Lennox-Gastaut) or progressive seizure types

**Alternative diagnosis**

- Syncope and convulsive syncope
- Psychogenic nonepileptic seizures
- Pain reactions, panic symptoms, dissociative episodes and other psychiatric states, sleep disorders, narcolepsy

Clues: Careful description of episodes by patient and observers (duration, prodromal symptoms, responsiveness and behaviors, recovery duration and symptoms)

from both the patient and observers. Here is a helpful list of some of the common features of seizures: the presence of warning symptoms (gastric or psychic auras are common with complex partial seizures); the presence of activity arrest, altered awareness, or diminished responsiveness during the seizure; the duration of the episodes (most epileptic seizures last less than 4 minutes); and whether the recovery period matches the severity of the seizure (usually several minutes for mild complex partial seizures, up to hours following tonic-clonic seizures).<sup>11</sup> Complex partial seizures are often preceded by brief epigastric or psychic (e.g., fear, déjà vu) auras and may be associated with activity arrest or with confusion and typical motor automatisms, such as fumbling, chewing, mild limb shaking, or head/eye deviation with postictal confusion. Tonic-clonic seizures are major convulsive episodes with severe stiffening and shaking and postictal confusion, often with tongue biting and postictal headaches.

In contrast to seizures, syncopal episodes often occur when patients are standing or changing posture, particularly when dehydrated or exhausted. Many patients become pale, briefly lightheaded or dizzy, and then collapse. Patients may experience brief myoclonic jerks, or even full convulsions if severely hypotensive.<sup>12</sup> Patients often have nausea and feel exhausted after a syncopal episode—less common features of seizures. Patients with psychogenic nonepileptic seizures (“pseudoseizures”) often have multiple features which are atypical for epileptic seizures, such as preictal headache, eye closure or fluttering, asynchronous or writhing movements, a rapid start-stop-start pattern of seizures, prolonged confusion, and stress triggers.<sup>13</sup> Psychogenic seizures often remain misdiagnosed when normal variant or drowsy EEG patterns are interpreted as epileptiform discharges.<sup>14</sup> Patients with pain reactions or panic reactions often have symptoms which precede their seizure-like behaviors. Uncertain diagnoses usually can be clarified with video-EEG.

**Determine treatment response (table 3)** Patients who fail treatment with high doses of several first-line AEDs appropriate for their seizure type have medication-resistant epilepsy. Some patients, however, appear to have drug resistance, but have not tolerated several AEDs due to multiple allergic reactions or due to drug side effects. These patients can usually find alternative therapies which they can tolerate. AEDs infrequently associated with allergic reactions are levetiracetam, topiramate, gabapentin, and divalproex.<sup>15</sup> Many patients, particularly the elderly, are sensitive to CNS-related medication side effects, such as dizziness, somnolence, and imbalance.<sup>16</sup> They often tolerate and respond to treatment with standard AEDs if AEDs are titrated very slowly to low doses.<sup>17</sup> AEDs associated with a low prevalence of dizziness and

**Table 2 Distinguishing seizures and syncope and other common causes of loss of awareness**<sup>32-34</sup>

	<b>Seizures</b>	<b>Syncope</b>	<b>Other: psychogenic seizures, pain reactions, dissociative</b>
<b>Premonitory symptoms</b>	Psychic or epigastric aura if partial-onset seizures	Lightheadedness	Often prolonged, pain may precede
<b>Accompanying symptoms/signs</b>	Activity arrest, unresponsiveness, cyanosis if convulsive	Diaphoresis, pallor, heat sensation, nausea	Panic, anxiety, pain
<b>Motor signs</b>	Rhythmic movements, focal head/eye version, chewing eyes often open, tongue biting if convulsive	Irregular myoclonus after onset, brief convulsion if severe (convulsive syncope)	Atypical or nonphysiologic movements (asymmetric limb jerks, eyelid fluttering), eyes often closed
<b>Duration</b>	Typically 20 seconds to 3 minutes	Seconds	Variable, often prolonged (many minutes to hours)
<b>Recovery</b>	Rapid to gradual recovery of alertness	Rapid (disorientation <5 minutes), general exhaustion	Typically rapid, repetitive start/stop common
<b>Common precipitants</b>	None, may vary with sleep or arousal, catamenial pattern in women	Sitting or standing, dehydration, exhaustion autonomic activation (pain or specific stress trigger)	General emotional and physical stress, pain
<b>Common associated conditions</b>	Prior brain injury or disorders	Presyncope	Psychiatric and cognitive disorders (mood disorders, anxiety/panic, postconcussive syndrome)
<b>Diagnostic tests</b>	Abnormal EEG, video EEG	ECG, tilt table	Normal EEG, video EEG, Personality Assessment Inventory
<b>Disorders</b>	Generalized seizures, partial-onset seizures, single seizures	Vasovagal, orthostatic hypotension, cardiac syncope (arrhythmia or loss of cardiac output)	Emotional and cognitive disorders

similar symptoms can also be used, such as lamotrigine and levetiracetam.<sup>18</sup> Patients often have dose-limiting CNS-related side effects due to combined effects of AEDs—patients can often successfully convert rapidly between the old and new medications.

**Identify symptomatic causes for medically resistant epilepsy and screen for aggravating factors** Patients with uncontrolled partial-onset seizures may benefit from high-resolution MRI with thin-section coronal fluid-attenuated inversion recovery (FLAIR) imaging to identify focal lesions associated with seizures, such as cortical dysgenesis, vascular abnormalities, and tumors. Cutaneous fibromas, renal lipomas, ataxia, ophthalmologic and other abnormalities can be clues suggesting possible genetic and developmental disorders associated with epilepsy. Patients with difficult-to-control seizures often have seizures triggered by severe stress and exhaustion, illness, sleep deprivation, or alcohol abuse. These factors are especially important triggers of generalized seizures.<sup>19</sup> Some patients have seizures because they regularly miss or do not take their AED doses—this may be an expression of abnormal coping or denial of their disorder or can represent a lack of understanding of the importance of maintaining steady AED concentrations to prevent seizures.

**Table 3** Possible strategies for treating medically resistant epilepsy

<b>Partial-onset seizures</b>
After failing 2 monotherapy trials with first-line AEDs, e.g., lamotrigine, extended-release carbamazepine, levetiracetam, oxcarbazepine
<ul style="list-style-type: none"> <li>• Additional monotherapy trial if high doses of previous AEDs poorly tolerated</li> <li>• Adjunctive treatment with a complementary AED</li> <li>• Match AED to patient profiles and needs, e.g., women of childbearing age, elderly patients, comorbid conditions (e.g., mood disorders, obesity, treatment interactions)</li> <li>• Minimize combination drug side effects (e.g., dizziness with high doses of oxcarbazepine and lacosamide) and drug interactions (e.g., increased free carbamazepine concentrations with divalproex)</li> <li>• AED options include topiramate, lacosamide, zonisamide, divalproex, phenytoin</li> <li>• Consider nonmedical therapy: surgery screening, vagal nerve stimulation, ketogenic/Atkins diet</li> <li>• Orphan and third-line AED options: clobazam, vigabatrin, barbiturates</li> </ul>
<b>Primary generalized epilepsy</b>
After failing 2 monotherapy trials with first-line AEDs, e.g., divalproex, levetiracetam, lamotrigine (ethosuximide for childhood/juvenile absence epilepsy)
<ul style="list-style-type: none"> <li>• Consider adjunctive therapy and possible conversion to monotherapy: topiramate, zonisamide</li> <li>• Additional adjunctive therapies: clonazepam, acetazolamide, clobazam</li> </ul>
<b>Severe symptomatic forms of epilepsy: multifocal, typically multiple seizure types</b>
After failing 2 monotherapy trials with first-line AEDs, e.g., divalproex, levetiracetam, lamotrigine, carbamazepine
<ul style="list-style-type: none"> <li>• Consider adjunctive therapy using combinations of broad and narrow spectrum AEDs, e.g., topiramate and divalproex, carbamazepine and levetiracetam, levetiracetam and lacosamide, divalproex and rufinamide</li> <li>• Nonmedical therapy: vagus nerve stimulation, ketogenic/Atkins diet therapy</li> <li>• Third-line adjunctive therapies: clonazepam, clobazam, felbamate</li> </ul>
<b>Corpus callosotomy (anterior 66% to 80%)</b>
Abbreviation: AED = antiepileptic drug.

Many patients take AEDs irregularly due to concerns about AED side effects or of pregnancy risks. These problems are usually resolved by reviewing the diagnosis and treatment options with patients along with a plan for monitoring for specific drug side effects, such as irritability with levetiracetam or weight gain with divalproex or concentration difficulty (with all AEDs). Careful attention to ameliorating side effects, use of weekly pill boxes, smart phone alarms, coupling dosing with dressing or other regular daily activities, and use of extended-release formulations to reduce dosing frequency can all improve drug adherence.

### Treating medically resistant epilepsy

Three case studies illustrate key principles in managing drug-resistant epilepsy.

**Case 1** A 22-year-old woman, with an initial tonic-clonic seizure at age 16, now has 4 seizures in 2 months, despite treatment with levetiracetam 1,500 mg/day. She previously had seizures and dizziness during treatment with oxcarbazepine 1,800 mg/day. A previous EEG was normal. She and her mother describe episodes with features typical of complex partial seizures: a psychic aura lasting several seconds followed by sudden 30- to 90-second periods of confusion with chewing



*Patients with uncontrolled partial-onset seizures may benefit from high-resolution MRI with thin-section coronal FLAIR imaging to identify focal lesions associated with seizures, such as cortical dysgenesis, vascular abnormalities, and tumors.*

motions and fumbling. Detailed questioning elicits a history of a prolonged febrile seizure at age 1 year. A previous MRI is reportedly normal.

**Analysis** She has typical complex partial seizures—chewing suggests temporal lobe involvement. This is confirmed by a new interictal EEG, which shows left temporal sharp waves. She strongly desires to be free of seizures in order to drive and to minimize future pregnancy risks. We can consider increasing the dose of levetiracetam or adding an AED approved for adjunctive treatment of partial-onset seizures. A wide range of other treatment options include lamotrigine, extended-release carbamazepine, lacosamide, zonisamide, and pregabalin.<sup>20</sup> Conversion to lamotrigine monotherapy is approved and has low risk for birth malformations. Divalproex (valproic acid) is a suboptimal AED for her, since it is associated with a 10% risk of birth defects and with weight gain. She is a student and could be treated with low doses of topiramate but may not wish to risk cognitive impairment with high doses. However, only a small percentage of patients who fail to respond to 2 or more AEDs become seizure-free.<sup>2,21</sup> Most patients with medial temporal lobe epilepsy become seizure-free after anterior temporal lobectomy or amygdalohippocampectomy.<sup>22</sup>

After discussing medical and nonmedical treatment options, she is referred for surgical screening with high-resolution MRI and video-EEG monitoring and begins lamotrigine. Coronal FLAIR MRI demonstrates probable left mesial temporal sclerosis and video-EEG shows left temporal seizure onset, suggesting she is a good surgical candidate. She continues to experience complex partial seizures while taking lamotrigine and then has a left anterior temporal lobectomy, subsequently entering remission. She has a minor decline in verbal memory after surgery and is able to obtain a driver's license. When the MRI shows mesial temporal sclerosis and preoperative verbal memory is impaired, chances are small that surgery will cause a severe or disabling cognitive deficit.

**Case 2** A 21-year-old man has had 3 tonic-clonic seizures in the past year despite treatment with lamotrigine 600 mg/day and previous treatment with levetiracetam 2,500 mg/day. He had his first tonic-clonic seizure at age 15, while playing video games. A brain MRI done prior to referral was normal. There is no family history of seizures.

**Analysis** Although referred for his tonic-clonic seizures, when asked, the patient reports having occasional clusters of bilateral arm and neck jerks in the morning. With myoclonic and tonic-clonic seizures, he is now diagnosed with probable juvenile myoclonic epilepsy (JME). This is confirmed by an EEG showing interictal 5 Hz generalized polyspike and slow wave bursts. His treatment adherence is demonstrated by a lamotrigine serum concentration of 14 mg/L (typical target range 4 to 10 mg/L). His seizures do not appear to be provoked by lifestyle factors such as sleep deprivation or excessive alcohol use. His seizures interfere with

*In countries with full financial resources, expensive AEDs and surgery are widely available, but lack of training to make the appropriate diagnosis and referral to an epilepsy center leaves many patients with inadequate treatment.*

work and driving. Seizures are usually controlled in JME so continued medical manipulation is worthwhile.<sup>23</sup>

He begins treatment with divalproex and has 2 seizures on a dose of 750 mg/day.<sup>24</sup> He has no seizures on divalproex 1,500 mg/day monotherapy in the next year; however, he develops marked weight gain. He has remained seizure-free since switching to zonisamide 300 mg/day.<sup>25</sup> In this case, ascertainment of the correct diagnosis leads the physician to trying more medication, with a reasonable prospect of achieving a favorable response.

**Case 3** A 25-year-old man with moderate intellectual disability and cerebral palsy has multiple daily seizures. Most are brief tonic and tonic/tonic seizures with bilateral arm and leg stiffening, often followed by brief loss of body tone; he also has several seizures each day with unresponsiveness and asymmetric bilateral shaking, often with left facial contraction. He occasionally falls and is injured during seizures and must wear a helmet. He is largely confined to a wheelchair. He is treated with divalproex 500 mg TID (98 mg/L) and clonazepam 0.5 mg TID. He previously had frequent seizures or was sedated during multiple AED trials, including phenytoin, felbamate, topiramate, lamotrigine, zonisamide, and rufinamide. He had fewer seizures while taking levetiracetam, but displayed aggressive behavior. An MRI showed mild scattered bilateral subcortical T2 abnormalities. EEG shows frequent independent left and right hemisphere and bilateral slow spike and wave bursts, along with mild diffuse slowing.

**Analysis** This patient fulfills criteria for diagnosis of Lennox-Gastaut syndrome. Patients with symptomatic generalized epilepsy often exhibit multiple seizure types, including tonic, complex partial, and tonic-clonic seizures along with significant cognitive impairment. His clinical condition provides evidence for diffuse brain injury and he is not a candidate for focal resective surgery. He has not responded to first- and second-line AEDs and will likely require AED polytherapy for the foreseeable future. He may benefit from intermittent adjuvant benzodiazepine treatment, preferably using nonsedating doses, for acute transient seizure exacerbations. He is a candidate for palliative therapy with vagal nerve stimulation (VNS)<sup>26</sup> and also may benefit from clobazam therapy.<sup>27,28</sup> He may also cooperate with treatment with the ketogenic/Atkins diet.<sup>29</sup> An anterior (66% to 80%) corpus callosotomy is also a good option, and offers the greatest chance for substantial reduction in seizure frequency, especially for the tonic and atonic seizures, though it also has the highest morbidity of the treatments mentioned.<sup>30</sup>

To minimize his need for emergency department visits, his caregivers were given lorazepam Intensol 2 mg/mL sublingual solution to treat acute repetitive seizures and a diazepam rectal formulation to treat occasional prolonged (>5 minutes) seizures. Lorazepam Intensol is only approved for treating anxiety, but has high bioavailability and is frequently used at 1 to 2 mg sublingual doses for acute seizure treatment. Patients with severe symptomatic epilepsy need careful monitoring for psychiatric and behavioral symptoms associated with underlying brain injury, seizures, and AED therapy. The patient had clobazam 10 mg TID substituted for clonazepam with moderate seizure reduction; he subsequently had VNS placed. He now has several minor myoclonic and brief focal seizures per week. He no longer falls

during his seizures and now is permitted to walk independently in his day and residential program.

### Limitations in care

In countries where resources limit access to health care, the above diagnostic considerations still apply, though the subsequent course of action might differ once a diagnosis of medically resistant seizures is made. Even if patients cannot afford the newest AEDs, inexpensive drugs are equally potent. Should inexpensive drugs prove intolerable, then financial limitations may prevent adequate treatment. Palliative and potentially curative options such as surgery might not be available. In countries with full financial resources, expensive AEDs and surgery are widely available, but lack of training to make the appropriate diagnosis and referral to an epilepsy center leaves many patients with inadequate treatment. In these countries, the wider selection of AEDs conveys advantages with regard to limiting adverse drug side effects and expanded treatment options. Patients with medically resistant epilepsy should be counseled not to drive and often need employment, educational, and psychological support.<sup>31</sup>

### REFERENCES

1. Kwan P, Arzimanogluou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2010;51:1069–1077.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. *N Engl J Med* 2000;342:314–319.
3. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. *Eur J Neurol* 2006;13:277–282.
4. Arts WF, Brouwer OF, Peters AC, et al. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. *Brain* 2004;127:1774–1784.
5. Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. community study. *Epilepsia* 1996;37:148–161.
6. Sperling MR. The consequences of uncontrolled epilepsy. *CNS Spectr* 2004;9:98–109.
7. Sperling MR, Harris A, Nei M, Liporace JD, O'Connor MJ. Mortality after epilepsy surgery. *Epilepsia* 2005;46:49–53.
8. Zarroli K, Tracy JJ, Nei M, Sharan A, Sperling MR. Employment after anterior temporal lobectomy. *Epilepsia* 2011;52:925–931.
9. Sander JW. The use of antiepileptic drugs: principles and practice. *Epilepsia* 2004;45:28–34.
10. Grubb BP, Gerard G, Roush K, et al. Differentiation of convulsive syncope and epilepsy with head-up tilt testing. *Ann Intern Med* 1991;115:871–876.
11. Theodore WH, Porter RJ, Albert P, et al. The secondarily generalized tonic-clonic seizure. *Neurology* 1994;44:1403–1407.
12. Wieling W, Thijs RD, van Dijk N, et al. Symptoms and signs of syncope: a review of the link between physiology and clinical clues. *Brain* 2009;132:2630–2642.
13. Syed TU, LaFrance Jr WC, Kahriman ES, et al. Can semiology predict psychogenic nonepileptic seizures? A prospective study. *Ann Neurol* 2011;69:997–1004.
14. Krauss GL, Abdallah A, Lesser R, et al. Clinical and EEG features of patients with EEG wicket rhythms misdiagnosed with epilepsy. *Neurology* 2005;64:1879–1883.
15. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. *Neurology* 2007;68:1701–1709.
16. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. *Neurology* 2004;62(suppl 2):S24–S29.
17. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. *Neurology* 2005;64:1868–1873.
18. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? *Acta Neurol Scand* 2006;114:157–168.
19. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. *Lancet* 2007;369:1016–1026.
20. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. *Lancet* 2007;369:1000–1015.
21. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee

- and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology* 2004;62:1261–1273.
22. Wiebe S, Blume WT, Girvin JP, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. *N Engl J Med* 2001;345:311–318.
  23. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. *J Neurol Neurosurg Psychiatry* 2004;75:75–79.
  24. Nicolson A, Marson AG. When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy. *Pract Neurol* 2010;10:208–218.
  25. Mantoan L, Walker M. Treatment options in juvenile myoclonic epilepsy. *Curr Treat Options Neurol* 2011;13:355–370.
  26. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. *J Neurosurg Epub* 2011.
  27. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. *Epilepsia* 2009;50:1158–1166.
  28. Montengero M, Arif H, Edmund N, et al. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. *Clin Neuropharmacol* 2008;31:333–338.
  29. Kossoff EH, Rho JM. Ketogenic diets: evidence for short- and long-term efficacy. *Neurotherapeutics* 2009;6:406–414.
  30. Asadi-Pooya A, Sharan A, Nei M, Sperling MR. Corpus callosotomy. *Epilepsy Behav* 2008;13:271–278.
  31. Jacoby A, Baker GA. Quality-of-life trajectories in epilepsy: a review of the literature. *Epilepsy Behav* 2008;12:557–571.
  32. Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. *J Am Coll Cardiol* 2002;40:142–148.
  33. Bergfeldt L. Differential diagnosis of cardiogenic syncope and seizure disorders. *Heart* 2003;89:353–358.
  34. Testa M, Lesser RP, Krauss GK, Brandt J. Personality Assessment Inventory among patients with psychogenic seizures and those with epilepsy. *Epilepsia* 2011;52:84–88.

## DISCLOSURES

Dr. Krauss serves as Vice President for the Epilepsy Study Consortium and on a safety monitoring board for Lundbeck Inc.; has received funding for travel from Eisai Inc. and a speaker honorarium from UCB; serves as Clinical Science Editor for *Epilepsy Currents*; receives publishing royalties for *The Johns Hopkins Digital EEG Atlas* (Johns Hopkins University Press, 2006, 2011); and receives research support for UCB, Eisai Inc., Sepracor Inc., Vertex Pharmaceuticals, Novartis, the NIH/NIA, and the Epilepsy Research Foundation. Dr. Sperling serves on scientific advisory boards for UCB and Vertex Pharmaceuticals; has received a speaker honorarium from UCB; serves as an Associate Editor for *Epilepsia*; serves as a consultant for Sunovion Pharmaceuticals; has served on speakers' bureaus for UCB and Pfizer Inc; and receives research support from UCB, Marinus Pharmaceuticals, Inc., Sunovion Pharmaceuticals, Sepracor Inc., Eisai Inc., Novartis, Lundbeck Inc., Vertex Pharmaceuticals, NeuroPace, Inc., Medtronic, Inc., and the NIH.

## Related articles from other AAN physician and patient resources

**Neurology<sup>®</sup>** ● [www.neurology.org](http://www.neurology.org)

**Self-treatment of benign paroxysmal positional vertigo: Semont maneuver vs Epley procedure.**  
*July 13, 2004;63:150-152.*

**Patient Page: Responsive neurostimulation for the treatment of seizures that do not respond to medication.**

*September 27, 2011;77:e79-e81.*

**Responsive cortical stimulation for the treatment of medically intractable partial epilepsy.**

*September 27, 2011;77:1295-1304.*

**Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.**

*May 3, 2011;76:1555-1563.*

**Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.**

*January 4, 2011;96:94-99.*

**Continuum<sup>®</sup>** ● [www.aan.com/go/elibrary/continuum](http://www.aan.com/go/elibrary/continuum)

**Epilepsy surgery and electronic devices.**

*June 2010;16:179-198.*

**Neurology Today<sup>®</sup>** ● [www.neurotodayonline.com](http://www.neurotodayonline.com)

**Responsive cortical stimulation found effective for intractable partial epilepsy.**

*September 15, 2011;11:25-27.*

# Neurology® Clinical Practice

## Treating patients with medically resistant epilepsy

Gregory L. Krauss and Michael R. Sperling

*Neurol Clin Pract* 2011;1;14-23

DOI 10.1212/CPJ.0b013e31823d07d1

This information is current as of December 1, 2011

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://cp.neurology.org/content/1/1/14.full.html">http://cp.neurology.org/content/1/1/14.full.html</a>
<b>References</b>	This article cites 33 articles, 9 of which you can access for free at: <a href="http://cp.neurology.org/content/1/1/14.full.html##ref-list-1">http://cp.neurology.org/content/1/1/14.full.html##ref-list-1</a>
<b>Citations</b>	This article has been cited by 2 HighWire-hosted articles: <a href="http://cp.neurology.org/content/1/1/14.full.html##otherarticles">http://cp.neurology.org/content/1/1/14.full.html##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Clinical Neurology</b> <a href="http://cp.neurology.org/cgi/collection/all_clinical_neurology">http://cp.neurology.org/cgi/collection/all_clinical_neurology</a> <b>Multiple sclerosis</b> <a href="http://cp.neurology.org/cgi/collection/multiple_sclerosis">http://cp.neurology.org/cgi/collection/multiple_sclerosis</a>
<b>Errata</b>	An erratum has been published regarding this article. Please see <a href="#">next page</a> or: <a href="/content/2/1/4.2.full.pdf">/content/2/1/4.2.full.pdf</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://cp.neurology.org/misc/about.xhtml#permissions">http://cp.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://cp.neurology.org/misc/addir.xhtml#reprintsus">http://cp.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurol Clin Pract* is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright Copyright © 2011 by AAN Enterprises, Inc.. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.



involvement likely including the thalami bilaterally to also account for her coma. Furthermore, if these lesions were indeed present, they would likely be picked up on CT scan, given that her symptomatology was progressive for 3 days prior to obtaining the study. Based on our experience, the clinical recovery began too rapidly for metabolic encephalopathies causing changes in the basal ganglia.

**Disclosures:** See original article for full disclosure list.

**Correspondence to:** Hocker.Sara@mayo.edu

1. Hocker S, Rabinstein AA. Cefepime neurotoxicity can mimic postanoxic coma with myoclonic status epilepticus. *Neurol Clin Pract* 2011;1:73–74.
2. Fishbain JT, Monahan TP, Canonico MM. Cerebral manifestations of cefepime toxicity in a dialysis patient. *Neurology* 2000;55:1756–1757.
3. Dixit S, Kurle P, Buyan-Dent L, Sheth RD. Status epilepticus associated with cefepime. *Neurology* 2000;54:2153–2155.

#### CORRECTION

##### Neurogenetics: Five new things

In the article “Neurogenetics: Five new things” by S. Jayadev et al. (*Neurology*<sup>®</sup> *Clinical Practice* 2011;1:41–48), there is an omission in figure 2, which should read “The copyright for this figure is held by the University of Washington.” The editorial staff regrets the omission.

#### CORRECTION

##### Treating patients with medically resistant epilepsy

In the article “Treating patients with medically resistant epilepsy” by Gregory L. Krauss and Michael R. Sperling (*Neurology*<sup>®</sup> *Clinical Practice* 2011;1:14–23), there is an error in the second to last line in table 3. “Corpus callosotomy (anterior 66% to 80%)” should be listed as another bullet point under treatment for “Severe symptomatic forms of epilepsy” below “Third-line adjunctive therapies.” The publisher regrets the error.